News und Analysen
Silence Therapeutics to Present at Jefferies Healthcare Conference
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
LivaNova to Present at the Goldman Sachs Global Healthcare Conference
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present in a fireside chat at the Goldman
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
Silence Therapeutics Reports First Quarter 2022 Results
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
LivaNova Reports First-Quarter 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2022.
Financial Summary and Highlights1
Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration
Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with
Hardman & Co Research: Tissue Regenix (TRX) On pathway to sustainability
LivaNova Initiates Targeted Commercial Launch of the Essenz Patient Monitor for Cardiopulmonary Bypass Procedures
LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today announced receipt of regulatory approvals and the start of a targeted commercial launch for the
New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+
According to a new study conducted by GSK, people age 50 or older in the US who have had COVID-19 may be at greater risk of developing shingles – a painful rash – compared to those who haven’t been
Silence Therapeutics to Present at 21st Annual Needham Virtual Healthcare Conference
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
Silence Therapeutics Announces Publication in the Journal of the American Medical Association Highlighting Results From SLN360 Phase 1 Study in Healthy Adults With High Lipoprotein(a)
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
LivaNova to Announce First-Quarter 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2022 results on Wednesday, May 4, 2022 at 1 p.m
Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501
Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with
Silence Therapeutics Reports Fourth Quarter and Full Year 2021 Results
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
LivaNova Announces 250th Unipolar Depression Patient Implanted in RECOVER Clinical Study
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 250th unipolar depression patient has been implanted in the RECOVER clinical study, “A P
Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 17, 2022
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
LivaNova Announces First Patient Implanted in OSPREY Clinical Study for Patients Coping with Obstructive Sleep Apnea
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the first patient implanted in the investigational device exemption (IDE) clinical study
LivaNova Reports Fourth-Quarter and Full-Year 2021 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2021.
For the fourth quarter of
Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (“siRNA”) therapeutics for the
Silence Therapeutics Announces SLN360 Phase 1 Data Accepted for Late-Breaking Presentation at the American College of Cardiology (ACC) Annual Scientific Session and Expo
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group Plc NPV
Routine Vaccination Rates in Teens and Adults Continue to Lag Behind Pre-Pandemic Levels, Follow-up Analysis Shows
Centers for Disease Control and Prevention (CDC)-recommended vaccinations for teens and adults continued to lag in 2020 and into the summer of 2021, according to a follow-up claims analysis
LivaNova to Announce Fourth-Quarter and Full-Year 2021 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth-quarter and full-year 2021 results on Wednesday, February